Syneos One® from Syneos Health

Syneos One is a dedicated interdisciplinary team providing seamless delivery of asset development solutions, bringing in the right resources and expertise spanning all clinical development, medical affairs, and commercialization services needed to bring products to market, address unmet patient needs and maximize value for stakeholders. 

Syneos Health is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture.

Find out more.

Partnering with Purpose

We Share Your Purpose. 
Your Goal Is Our Goal. 

A world-class organization of proactive, trusted experts, empowered with tools and technologies to deliver.

Focus on what matters to you most – getting life-changing therapies to patients.

Good Science Is Not Good Enough

A comprehensive guide for pre-commercial companies looking to develop a value creation story to differentiate in a complex funding environment 

Dealmakers’ Intentions 2024

Learn more about 2024 expectations of biopharma decision-makers in this forward-looking measure of dealmaking activity 

New Opportunities for Value Creation

An overview of strategic and operational implications for the biotech C-suite looking to succeed in an increasingly competitive environment  

Reinventing the End-to-End Model

A small biotech customer partnered with Syneos One to bring its life-changing asset to market. Our team navigated Phase II trials and helped them on the path to bringing this important drug to market. 

For more information on partnership opportunities at other FT Live events, get in touch today to see how you can get involved.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice